Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 7

1.

Intravenous delivery of adeno-associated viral vector serotype 9 mediates effective gene expression in ischemic stroke lesion and brain angiogenic foci.

Shen F, Kuo R, Milon-Camus M, Han Z, Jiang L, Young WL, Su H.

Stroke. 2013 Jan;44(1):252-4. doi: 10.1161/STROKEAHA.112.662965. Epub 2012 Dec 18.

2.

The advent of AAV9 expands applications for brain and spinal cord gene delivery.

Dayton RD, Wang DB, Klein RL.

Expert Opin Biol Ther. 2012 Jun;12(6):757-66. doi: 10.1517/14712598.2012.681463. Epub 2012 Apr 20. Review.

3.

Angiogenesis-regulating microRNAs and Ischemic Stroke.

Yin KJ, Hamblin M, Chen YE.

Curr Vasc Pharmacol. 2015;13(3):352-65. Review.

4.

New vectors and strategies for cardiovascular gene therapy.

Jazwa A, Jozkowicz A, Dulak J.

Curr Gene Ther. 2007 Feb;7(1):7-23. Review.

5.

Gene therapy for the CNS using AAVs: The impact of systemic delivery by AAV9.

Saraiva J, Nobre RJ, Pereira de Almeida L.

J Control Release. 2016 Nov 10;241:94-109. doi: 10.1016/j.jconrel.2016.09.011. Epub 2016 Sep 13. Review.

PMID:
27637390
6.

AAV-mediated gene therapy for atherosclerosis.

Lehrke M, Lebherz C.

Curr Atheroscler Rep. 2014 Sep;16(9):434. doi: 10.1007/s11883-014-0434-0. Review.

PMID:
25085755
7.

Evaluation of Gene Therapy as an Intervention Strategy to Treat Brain Injury from Stroke.

Craig AJ, Housley GD.

Front Mol Neurosci. 2016 May 24;9:34. doi: 10.3389/fnmol.2016.00034. eCollection 2016. Review.

Supplemental Content

Support Center